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A large multi-ethnic genome-wide association
study identifies novel genetic loci for intraocular
pressure
Hélène Choquet1, Khanh K. Thai1, Jie Yin1, Thomas J. Hoffmann2,3, Mark N. Kvale2, Yambazi Banda2,
Catherine Schaefer1, Neil Risch1,2,3, K. Saidas Nair4, Ronald Melles5 & Eric Jorgenson 1
Elevated intraocular pressure (IOP) is a major risk factor for glaucoma, a leading cause of
blindness. IOP heritability has been estimated to up to 67%, and to date only 11 IOP loci have
been reported, accounting for 1.5% of IOP variability. Here, we conduct a genome-wide
association study of IOP in 69,756 untreated individuals of European, Latino, Asian, and
African ancestry. Multiple longitudinal IOP measurements were collected through electronic
health records and, in total, 356,987 measurements were included. We identify 47 genome-
wide significant IOP-associated loci (P< 5 × 10−8); of the 40 novel loci, 14 replicate at
Bonferroni significance in an external genome-wide association study analysis of 37,930
individuals of European and Asian descent. We further examine their effect on the risk of
glaucoma within our discovery sample. Using longitudinal IOP measurements from electronic
health records improves our power to identify new variants, which together explain 3.7% of
IOP variation.
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E levated intraocular pressure (IOP) is the main modifiablerisk factor in glaucoma development and progression1, 2, aleading cause of blindness worldwide3. IOP is controlled by
balancing aqueous humor production by the ciliary body with
drainage through the structures located at the junction where the
cornea meets the iris4. Inefficient aqueous humor drainage leads
to elevated IOP, which, in turn, contributes to glaucomatous
neurodegeneration characterized by progressive loss of retinal
ganglion cells and corresponding visual field damage. The
mechanisms controlling aqueous humor dynamics and IOP reg-
ulation are still poorly understood. Gene identification may help
uncover the mechanisms underlying IOP variation, and, conse-
quently, glaucoma susceptibility.
Twin and family studies indicate that IOP has a moderate
genetic component, with heritability estimates ranging from 0.29
to 0.675. Genetic association studies have reported 11 loci asso-
ciated with IOP6–13, accounting for up to 1.5% of the variance for
this ocular trait8. The limited proportion of variance explained by
known loci suggests that additional loci remain to be discovered.
IOP can vary owing to different factors, including time of day
at which the measurement was taken, corneal thickness, medi-
cations, different measurement techniques that were employed
(i.e., Goldmann applanation tonometer, Tono-Pen XL, or others),
and demographic factors such as age and racial/ethnic back-
ground14–16. These sources of variability may reduce the power to
detect IOP loci in studies that rely on a single, cross-sectional
measurement for each study participant. Incorporating informa-
tion from multiple longitudinal measurements collected through
electronic health records has been shown to improve the preci-
sion of the characterization of phenotypes by reducing mea-
surement error (such as for blood pressure), and, in turn, improve
the power to detect novel associations with genetic loci17.
Here, we undertake a GWAS of IOP in the large and ethnically
diverse Genetic Epidemiology Research in Adult Health and
Aging (GERA) cohort, including 356,987 IOP measurements
from 69,756 individuals (not treated with IOP lowering medica-
tion), the largest sample to date. We then validate genome-wide
significant associations using summary statistics from an external
independent GWAS meta-analysis of 37,930 individuals of Eur-
opean and Asian descent11. We further examine their effect on
the risk of glaucoma within our GERA discovery sample.
Through the increase in sample size in the current study and the
use of multiple IOP measurements, we reason that our study
would identify a substantial number of novel genetic loci asso-
ciated with IOP. A better understanding of the genetic factors
underlying IOP can provide insight into the risk factors that
underlie glaucoma susceptibility and progression.
Results
GERA cohort. We conducted the primary discovery analysis in
69,756 individuals from four race/ethnicity groups (non-Hispanic
whites, 81.5%; Hispanic/Latinos, 8.2%; East Asians, 7.3%; and
African-Americans, 3.0%) in the GERA cohort (Table 1). The
GERA cohort is part of the Kaiser Permanente Research Program
on Genes, Environment, and Health (RPGEH), an unselected
cohort of adult participants who are members of an integrated
health care delivery system (Kaiser Permanente Northern Cali-
fornia), with ongoing longitudinal records from vision examina-
tions. The 69,756 untreated GERA subjects had a total of 356,987
IOP measurements (an average of 5.8 IOP measurements per
individual). In this analysis, we used the mean IOP of both eyes
and selected the median of the mean IOP of both eyes (Fig. 1 and
Table 1). On average, IOP levels were slightly higher in females
than in males across the race/ethnicity groups, and East Asian
individuals had lower levels of IOP compared to the other groups.
Novel IOP loci in GERA. In our discovery GWAS analysis, we
identified 47 independent genome-wide significant (P< 5 × 10–8)
loci associated with IOP in the trans-ethnic meta-analysis; the
genomic inflation factor, λ, of 1.12, is reasonable for a sample of
this size (Fig. 2, Table 2 and Supplementary Fig. 1a). Of the 47
identified loci, 40 were novel (85.1%), that is, not previously
reported to be associated with IOP. These 47 associations with
IOP were also examined in each individual race/ethnicity group
(Supplementary Table 1 and Supplementary Fig. 1b–e).
Replication in an independent external cohort. We then tested
the 40 lead single-nucleotide polymorphisms (SNPs) representing
each of the 40 independent loci for replication in an independent
external meta-analysis consisting of 37,930 individuals of Eur-
opean and Asian descent from 19 studies11. Of the 40 novel IOP-
associated SNPs, 39 were associated with the same direction of
effect in the replication sample, and 14 replicated at Bonferroni
significance (P< 0.0013 = 0.05/40) (Table 2).
Conditional and epistasis analyses. We next searched for addi-
tional genome-wide significant SNPs within a 2Mb window
(±1.0 Mb with respect to the lead SNP) including the 47 lead
SNPs identified in the discovery GERA trans-ethnic GWAS
analysis as covariates. We did not identify any additional
genome-wide significant SNPs; however, we identified 12 SNPs
with suggestive evidence of association with IOP that appeared to
be independent signals (P< 0.0001 corresponding to an estimate
of ~500 independent variants per locus for 2Mb interval sur-
rounding each of our original signals) (Supplementary Table 2).
We then conducted an epistasis analysis of all pairs of lead SNPs
in each race/ethnicity group, and we did not observe significant
epistatic interactions between IOP SNPs after Bonferroni cor-
rection (P< 1.2 × 10–5 = 0.05/(((47*46)/2)*4)).
Effect of the 47 IOP-associated loci on glaucoma. To investigate
whether the 47 lead IOP-associated SNPs were also associated
with primary open-angle glaucoma (POAG) susceptibility, we
performed a case–control analysis in GERA including 2,338
POAG cases (normal and high-tension glaucoma) and 58,172
controls (Table 1). Forty-two of the 47 genome-wide significant
IOP loci (89.4%) show a directionally consistent effect in the
POAG GWAS. In particular, we found associations with glau-
coma at a Bonferroni level of significance (P< 0.00106 = 0.05/47)
for 6 SNPs. This included one SNP at a genome-wide level of
significance for a previously identified locus at TMCO1 (P = 2.8 ×
10−8 for rs6668108) (Supplementary Table 3). The two lead SNPs
for TMCO1 (rs4656461 and rs7518099) previously reported to be
associated with POAG at genome-wide significance18, 19, were
strongly correlated with our lead SNP rs6668108 in European-
Ancestry populations (R2 = 0.99 and 1.0, respectively) (Supple-
mentary Table 4). Other Bonferroni significant loci included
AFAP1 (P = 3.6 × 10−6 for rs28795989), ABCA1 (P = 5.4 × 10−6 for
rs2472493), and GAS7 (P = 5.0 × 10−7 for rs9913911) (Supple-
mentary Table 3). The two lead SNPs for AFAP1 (rs4619890 and
rs11732100) previously reported to be associated with POAG at
genome-wide significance18, 20, were moderately correlated with
our lead SNP rs28795989 in European-Ancestry populations (R2
= 0.25 and 0.51, respectively) (Supplementary Table 4). Con-
sistent with previous studies18, 20, we identified SNP rs2472493 as
the lead SNP at the ABCA1 locus. Our lead SNP rs9913911 in
GAS7 was relatively close (10.7 kb) to SNP rs9897123 previously
reported18, and was in linkage disequilibrium (LD) (R2 = 0.54, D’
= 0.95). We also found supportive evidence for the previously
identified locus on FOXC1 (P = 2.9 × 10−4) (Supplementary
Table 3) with the same lead SNP rs2745572 reported by Bailey
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et al.18 (Supplementary Table 4). All above-mentioned alleles
associated with higher IOP levels also raised glaucoma risk
(Supplementary Table 3).
Genetic association with related traits and eye diseases. In
addition to glaucoma risk, several loci for which the associations
with IOP reached genome-wide significance were already known
to influence the variation of ocular traits, or eye diseases (Sup-
plementary Table 4). These findings extend previous studies
showing overlapping GWAS regions between POAG and related
traits8, 11, 18, 21, 22. The current study identified a genome-wide
significant signal with IOP at EFEMP1 on chromosome 2.
Common variants in EFEMP1 (rs3791679 and rs1346786) have
been shown to be associated with cup area, a specific optic disc
measurement describing optic nerve morphology11, 12. Our lead
SNP rs7426380 at EFEMP1 was in LD with these two SNPs in
European-Ancestry populations (R2 = 0.33, D’ = 0.98 for
rs3791679, and R2 = 0.49, D’ = 0.98 for rs1346786) (Supplemen-
tary Table 4). Further, among our novel IOP loci, six have been
previously associated with central corneal thickness, including
COL4A3, FAM46A-IBTK, ARID5B, FOXO1, SMAD3, and BANP-
ZNF46921, 23–26. Except for SNP rs1538138 at FAM46A-IBTK, all
the lead SNPs at those loci previously associated with central
corneal thickness were in high LD with our lead SNPs in
European-Ancestry populations (R2 ranged from 0.97 to 0.99, and
D’ ranged from 0.99 to 1.0) (Supplementary Table 4). We also
identified a genome-wide significant signal with IOP on
chromosome 9 at GLIS3, which is involved in the development of
the eye27, and has been recently identified as a new susceptibility
locus for primary angle-closure glaucoma28. Our lead SNP
rs2224492 at GLIS3 was correlated with the strongest SNP
rs736893 reported by Khor et al.29 (R2 = 0.71, D’ = 0.85), and the
two SNPs were relatively close (20.5 kb apart). These findings
suggest a shared genetic etiology between IOP and related traits;
further investigations could help to better understand their shared
mechanisms and biological pathways.
Our study also identified novel IOP loci that have been
previously involved in autosomal dominant Mendelian ocular
conditions. Indeed, deleterious mutations in FOXC1 and PITX2
can cause Axenfeld-Rieger syndrome, an anterior segment
dysgenesis disorder characterized by anomalies in the anterior
chamber angle, including defects in the drainage structures of the
eye30–32. A major consequence of angle dysgenesis is an increase
in IOP leading to the development of early-onset glaucoma, with
FOXC1 mutation carriers having a younger age at diagnosis in
comparison with PITX2 mutation carriers (6 vs. 18 years,
respectively)33. Therefore, it is likely that common variants in
FOXC1 and PITX2 mildly impact the drainage structures, and, in
combination with defects of other genetic variants contribute to
elevated IOP. Thus, it seems that there is a continuous spectrum
of genetic predisposition to elevated IOP and related traits, from
monogenic causative variants with high penetrance, to common
polygenic variants with moderate to low penetrance.
Gene expression in human ocular tissues. To prioritize genes
for further investigation, we first identified the 95% credible set of
variants in each of the 47 IOP loci (Supplementary Data 1—See
Methods). We then examined expression levels of the genes in
the 47 IOP loci that contained associated 95% credible set var-
iants in human ocular tissues using two publicly available data-
bases: the OTDB (Ocular Tissue Database)34, and EyeSAGE35, 36.
According to the Ocular Tissue Database34, most of the identified
genes were expressed in most ocular tissues, and some
genes showed varied expression levels across ocular tissues
(Supplementary Table 5). For instance, ANTXR1 was highly
expressed in the sclera, and FMNL2 was highly expressed in the
optic nerve and optic nerve head. ANTXR1 and FMNL2
were both novel loci identified in the present study which repli-
cated in the external study. On average, the identified genes
were most strongly expressed in the optic nerve head (mean±
SD: 90.2± 85.1), followed by the trabecular meshwork (mean±
SD: 82.5± 63.7) (Supplementary Table 5—Supplementary Fig. 2).
The trabecular meshwork is located in the angle of the
anterior chamber, and is responsible for draining the aqueous
humor from the eye. Because of its role, it is a crucial determinant
of IOP37.
Table 1 Characteristics of GERA subjects with intraocular pressure measurements by sex, and race/ethnicity group
Participants N (%) Median IOP (od,os) (mmHg) mean
± SD
Age at median IOP (years) mean
± SD
N IOP Meas. mean±
SD
All 69,756 (100.0) 15.11± 2.71 68.36± 12.53 5.75± 6.76
Sex Female 41,958 (60.1) 15.25± 2.65 67.00± 13.04 5.80± 6.72
Male 27,798 (39.9) 14.90± 2.78 70.42± 11.41 5.67± 6.81
Race/ethnicity NHW 56,819 (81.5) 15.16± 2.72 69.33± 12.06 5.81± 6.93
H/L 5,748 (8.2) 15.22± 2.67 63.98± 13.85 5.33± 5.90
EAS 5,119 (7.3) 14.34± 2.54 63.65± 13.65 5.63± 5.83
AFR 2,070 (3.0) 15.31± 2.81 65.56± 12.79 5.62± 6.16
Glaucoma Cases 2,338 15.85± 2.90 75.07± 9.43 17.49± 11.21
Controls 58,172 14.91± 2.61 67.80± 12.78 4.83± 5.72
N, number; SD, standard deviation; od, right eye; os, left eye; meas, measurements; NHW, non-Hispanic whites; H/L, Hispanic/Latinos; EAS, East Asians; AA, African-Americans
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Fig. 1 Distribution of the median of the mean (left, right) of IOP in GERA
cohort subjects. A total of 356,987 IOP measurements from 69,756
individuals were used to create this chart showing the normal distribution
of the median of the IOP mean from both eyes
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Gene prioritization and gene set enrichment analysis. To
translate the 47 IOP genetic loci identified in the current study
into biological insights, we used DEPICT38, which is not driven
by phenotype-specific hypotheses. This integrative tool considers
multiple lines of complementary evidence to systematically
prioritize the most likely causal genes at associated loci, highlight
enriched pathways, and identify tissues/cell types in which genes
from associated loci are highly expressed. Gene prioritization
analysis did not detect genes within the 47 identified loci to
prioritize after false-discovery rate (FDR) correction; however,
nominal evidence was found for seven genes, including COL6A1,
FOXO1, GLIS3, EFEMP1, CAV2, ANTXR1, and LPP
(Supplementary Table 6). Gene set enrichment analysis high-
lighted the “abnormal vascular endothelial cell morphology”
pathway as the pathway in which the genes’ actions more likely
affect IOP phenotype (P = 6.2 × 10–9; at FDR< 5%) (Supple-
mentary Table 7). Tissue and cell type enrichment analysis
detected a number of nominal enrichments (Supplementary
Table 8).
Replication of previous IOP GWAS results. We also investi-
gated a total of 13 independent SNPs within 11 loci associated
with IOP at a genome-wide significance level in previous stu-
dies6–9, 11, 13, 22 (Supplementary Table 9). Eight of the 13
Table 2 Lead genome-wide significant SNP for each independent locus identified in the GERA discovery GWAS of IOP
SNP Chr Pos Locus Alleles GERA discovery
cohort
External
replication cohort
Discover
+replication meta-
analysis
β P value β P value β P value
rs1866758 1 42318868 HIVEP3 T/C 0.10 1.2 × 10−9 0.07 0.0063 0.09 4.6 × 10−11
rs6668108 1 165691320 LOC440700-TMCO1 A/G 0.22 1.0 × 10−20 0.24 8.2 × 10−11 0.23 6.8 × 10−30
rs596169 1 219147419 MIR548F3 A/G −0.18 1.4 × 10−9 −0.18 0.0006 −0.18 3.5 × 10−12
rs115179432 2 33348679 LTBP1 A/G −0.19 2.7 × 10−10 −0.10 0.07 −0.17 1.3 × 10−10
rs7426380 2 56095010 EFEMP1 A/G −0.11 3.5 × 10−12 −0.07 0.0059 −0.10 2.1 × 10−13
rs6732795 2 69411517 ANTXR1 A/C −0.10 2.6 × 10−10 −0.09 0.0002 −0.10 2.0 × 10−13
rs55692468 2 153361375 FMNL2 T/G −0.09 7.7 × 10−9 −0.10 1.3 × 10−5 −0.09 5.4 × 10−13
rs1035673 2 218675533 TNS1 T/C −0.10 5.0 × 10−10 −0.07 0.0023 −0.09 6.9 × 10−12
rs143937055 2 228143966 COL4A3/LOC654841 TTTG/T 0.10 1.2 × 10−9 0.10 0.0002 0.10 9.0 × 10−13
rs7599762 2 238322885 COL6A3 G/C −0.13 4.3 × 10−9 −0.05 0.15 −0.10 1.2 × 10−8
rs11710845 3 150065280 LINC01214/TSC22D2 C/T 0.10 8.2 × 10−9 0.05 0.08 0.09 6.9 × 10−9
rs7635832 3 171989276 FNDC3B T/G 0.24 1.5 × 10−36 0.22 6.6 × 10−13 0.23 9.3 × 10−48
rs9853115 3 186131600 DGKG-LINC02052 T/A 0.11 4.1 × 10−13 0.08 0.0009 0.10 2.5 × 10−15
rs13076750 3 188059443 LPP A/G 0.12 6.3 × 10−13 0.06 0.0118 0.10 1.3 × 10−13
rs28795989 4 7891545 AFAP1 A/G 0.14 4.9 × 10−18 0.10 0.0001 0.13 6.0 × 10−21
rs17527016 4 111963719 PITX2-C4orf32 C/T 0.11 5.4 × 10−9 0.09 0.0137 0.10 2.6 × 10−10
rs4865762 5 52582931 MOCS2/FST C/A 0.12 2.8 × 10−14 0.08 0.0006 0.11 1.4 × 10−16
rs73220188 5 108053612 FBXL17/FER T/C 0.15 2.2 × 10−10 0.14 0.0001 0.15 1.4 × 10−13
rs2745572 6 1548369 FOXF2-FOXCUT A/G 0.11 5.9 × 10−12 0.12 1.3 × 10−6 0.11 4.4 × 10−17
rs1396046 6 51536992 PKHD1 G/A −0.10 6.6 × 10−10 −0.04 0.07 −0.08 7.0 × 10−10
rs2875087 6 82616083 FAM46A-IBTK C/T 0.13 6.0 × 10−17 0.07 0.0037 0.11 9.0 × 10−18
rs141917145 6 113375846 near RFPL4B AAAGAAACAAG/A 0.10 7.2 × 10−9 0.04 0.13 0.08 1.2 × 10−8
rs1509922 7 80858944 SEMA3C-HGF G/A 0.10 2.7 × 10−11 0.06 0.0197 0.09 5.7 × 10−12
rs6968419 7 115823384 TFEC-TES A/G 0.13 8.3 × 10−18 0.09 0.0001 0.12 1.8 × 10−20
rs10105844 8 108290872 ANGPT1 G/A −0.10 2.0 × 10−8 −0.08 0.0025 −0.09 2.2 × 10−10
rs2224492 9 4237546 GLIS3 A/G −0.13 4.9 × 10−16 −0.06 0.0117 −0.11 3.8 × 10−16
rs1831902 9 13558317 FLJ41200-LINC00583 C/T −0.12 3.6 × 10−10 −0.07 0.0160 −0.10 5.3 × 10−11
rs2472493 9 107695848 AK311445/ABCA1 G/A 0.17 1.1 × 10−28 0.17 2.3 × 10−13 0.17 1.8 × 10−40
rs11014632 10 25877651 GPR158 A/G 0.08 2.2 × 10−8 0.03 0.18 0.07 5.3 × 10−8
rs5785510 10 63837289 ARID5B CA/C 0.11 2.2 × 10−12 0.10 9.7 × 10−5 0.11 1.0 × 10−15
rs66479974 10 95049397 CYP26A1-MYOF CAG/C 0.09 2.4 × 10−8 0.09 0.0005 0.09 4.8 × 10−11
rs79390637 11 47456867 PSMC3/RAPSN C/A 0.14 5.3 × 10−17 0.10 0.0003 0.13 1.4 × 10−19
rs199800298 11 120348583 ARHGEF12 AG/A −0.13 3.6 × 10−16 −0.13 5.9 × 10−7 −0.13 1.2 × 10−21
rs7977237 12 43700341 LOC105369739-ADAMTS20 T/A 0.09 3.8 × 10−8 0.04 0.087 0.08 2.8 × 10−8
rs74481774 12 108987230 TMEM119 A/G 0.31 2.4 × 10−8 0.08 0.41 0.25 1.5 × 10−7
rs9552680 13 23235285 LINC00424-BASP1P1 C/T −0.09 2.2 × 10−8 −0.06 0.0113 −0.08 1.2 × 10−9
rs11616662 13 41119466 FOXO1 G/A 0.21 6.6 × 10−17 0.12 0.0056 0.19 8.1 × 10−18
rs12912045 15 67467297 SMAD3 C/T −0.12 4.0 × 10−11 −0.14 2.3 × 10−7 −0.12 6.2 × 10−17
rs72755233 15 100692953 ADAMTS17 G/A −0.24 9.0 × 10−20 −0.19 0.0023 −0.23 1.2 × 10−21
rs75828804 16 77591935 ADAMTS18-NUDT7 G/A −0.18 1.7 × 10−11 −0.19 0.0004 −0.18 2.9 × 10−14
rs12926024 16 88331309 BANP-ZNF469 T/C −0.15 1.1 × 10−11 −0.07 0.0062 −0.11 4.2 × 10−12
rs4790881 17 2068932 SMG6 C/A 0.11 9.0 × 10−12 0.06 0.0100 0.10 1.3 × 10−12
rs34629349 17 4829560 INCA1 C/A 0.12 2.9 × 10−13 0.07 0.0063 0.11 2.2 × 10−14
rs9913911 17 10031183 GAS7 A/G 0.21 1.4 × 10−42 0.17 7.0 × 10−12 0.20 2.1 × 10−52
rs11659764 18 53335512 TCF4-LINC01415 T/A 0.26 4.0 × 10−13 0.20 0.0007 0.24 1.8 × 10−15
rs3918508 20 37912667 LINC01734/LINC01370 G/A 0.09 1.3 × 10−9 −0.02 0.42 0.06 3.1 × 10−6
rs2839082 21 47442334 COL6A1-COL6A2 C/T 0.09 3.5 × 10−9 0.04 0.14 0.07 7.8 × 10−9
SNP, single-nucleotide polymorphism; Chr, chromosome; GERA, Genetic Epidemiology Research in Adult Health and Aging; GWAS, genome-wide association studies; Pos, position; β, beta; P, P value
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replicated at a genome-wide level of significance in our GERA
trans-ethnic meta-analysis (including TMCO1 rs7555523,
FNDC3B rs6445055, CAV1 rs10258482 and rs423660, ABCA1
rs2472493, ARHGEF12 rs58073046, GAS7 rs9913911 and
rs11656696) and four at Bonferroni significance (P< 0.05/13 =
0.0038) (Supplementary Table 9). In contrast, GLCCI1/ICA1
rs59072263 on chromosome 7, which was reported as genome-
wide significant in a previous GWAS of IOP6, was not associated
with IOP in the current study (P = 0.54).
Heritability estimate and variance explained. Using GCTA39,
we estimated array heritability in the non-Hispanic white sample
to be 24.6% (SE = 1.0%). We then determined the proportion of
variance explained by lead variants in each of the four race/eth-
nicity groups (Supplementary Table 10). We first estimated the
variance explained using the 47 lead variants identified in the
current study, which was highest in the non-Hispanic white
group (3.66%), followed by East Asians (3.54%), Hispanic/Latinos
(3.01%), and African-Americans (2.80%). For comparison, we
conducted the same analysis for the previously reported lead
SNPs, with the highest proportion of variance explained in East
Asians (1.17%), non-Hispanic whites (1.09%), Hispanic/Latinos
(0.84%), and African-Americans (0.25%). To determine how
incorporating multiple measurements affected the proportion of
variance explained, we estimated the variance explained by the 47
lead variants using a single, randomly chosen IOP measurement
for each individual in the sample. The proportion of variance
explained decreased in each group to 2.88% in non-Hispanic
whites, 2.58% in East Asians, 2.60% in Hispanic/Latinos, and
2.65% in African-Americans.
Discussion
In the large, ethnically diverse GERA cohort, we discovered 40
novel genome-wide significant IOP loci, of which 14 replicated at
Bonferroni level of significance in an independent external meta-
analysis11. We further examined their effect on the risk of
glaucoma within our discovery sample, and summarized genetic
associations at these IOP loci with other vision disorders and
related traits previously reported in the literature. We also con-
firmed the association of variants with IOP in 10 loci previously
reported, including TMCO1, FNDC3B, CAV1, ABCA1,
FAM125B/LMX1B, ABO, ARHGEF12, ADAMTS8, GAS7, and on
chromosome 11p11.2 encompassing several genes7–9, 11, 13, 22.
Our findings extend previous studies showing the important
role for specific components of the drainage structure in con-
trolling IOP4, 37. The meshwork is primarily composed of three
layers, with the outermost region of the trabecular meshwork
lined by the endothelial cells, forming the inner wall of Schlemm’s
canal (a modified capillary blood vessel that forms intra- and
intercellular pores). Aqueous humor passes through these dif-
ferent tissue layers and flows into the Schlemm’s canal. Con-
sistent with a role of the drainage tissue in IOP regulation, some
of the genes identified in the current study were, on average, more
expressed in the trabecular meshwork than other ocular tissues
(e.g., TNS1, LPP, GLIS3, and FOXO1). To date, the cellular sig-
naling pathways that maintain the outflow of aqueous humor and
IOP homeostasis are not well understood40, 41. Resistance to
aqueous humor flow into the Schlemm’s canal maintains the
physiological IOP of the eye. Although the identity of cell types
and tissue layers supporting conventional outflow is well estab-
lished, the specific contribution of the individual layers toward
generating resistance to aqueous flow remains unclear. Based on
current views, resistance to aqueous humor outflow is imparted at
the region just proximal to the Schlemm’s canal42–44. In the
disease state, increased resistance to aqueous humor outflow is
thought to contribute to elevated IOP. Our in silico results pro-
vide compelling evidence that support “abnormal vascular
endothelial cell morphology” as the pathway in which the genes’
actions at the identified loci more likely affect IOP. Together,
these findings suggest a potential role for Schlemm’s canal
endothelial cells in imparting resistance to aqueous humor out-
flow and thereby influencing IOP regulation.
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The current study also highlights potential strong candidate
genes for further investigation among the novel IOP loci identi-
fied, which replicated in the external sample, with substantial
biological evidence from the literature and our in silico results.
Some of these genes belong to cellular signaling pathways critical
for IOP regulation, and involving components of the extracellular
matrix (ECM), and endothelial cell function4, 40, 41. ANTXR1
encodes a type I transmembrane protein known as anthrax toxin
receptor 1, which is involved in the vascular endothelial growth
factor signaling and ECM synthesis to control mechanisms of
connective tissue development and homeostasis45, 46. Similarly,
TCF4, that encodes transcription factor 4, is a major risk factor
for Fuchs endothelial corneal dystrophy, a corneal disease leading
to visual impairment and blindness47–50, and owing, notably, to
an excessive accumulation of ECM51. Thus, mutations in
ANTXR1 and TCF4 could contribute to increased resistance,
through an excessive synthesis or accumulation of ECM in the
ocular drainage tissue, thereby impeding flow of aqueous humor
and resulting in elevated IOP.
Our study also led to the identification of genes belonging to
cellular signaling pathways linked to cellular contraction and
adhesion, and cell–cell, cell–ECM contact or adhesion4, 40, 41.
Cellular contraction and relaxation is thought to modulate per-
meability of trabecular meshwork cells and aqueous humor out-
flow52. FMNL2 encodes a formin-related protein, named formin
like 2, and formin-related proteins have been implicated in actin
nucleation and elongation as well as in lamellipodia protrusion53.
Because of its action on the cytoskeleton, FMNL2 could have a
crucial role in the contractile mechanism in the conventional
outflow pathways and adjoining layers, affecting the outflow
resistance and IOP. Thus, we speculate that mutations in this
gene could modify the contractile properties of the tissue layers
that make up the drainage structure of the eye, resulting in IOP
modulation. Follow-up experiments of this potential candidate
gene using in vivo animal models would aid in our understanding
of its role in the regulation of IOP and glaucoma development.
Our study was limited by its restriction to common variants
(minor allele frequency ≥ 1%), which did not allow us to identify
lower frequency variants that contribute to variation in IOP.
Indeed, a previous study has conducted an exome-wide associa-
tion analysis and identified less common variants associated with
IOP, in particular in the CAV1/CAV2 region7. In addition, our
study was limited in its replication of prior GWAS findings by the
smaller size of the replication cohort available, somewhat redu-
cing confidence in the novel associations found in our larger
discovery cohort. This concern is mitigated by findings from our
case–control analysis of glaucoma, which show that 15 of the
novel loci associated with IOP are also associated with glaucoma
at Bonferroni or nominal level of significance, including three loci
(AFAP1, FOXC1, and PKHD1) previously found in association
with glaucoma. In addition, loci associated with IOP were asso-
ciated with a number of other eye conditions and traits consistent
with a plausible role in affecting IOP. These limitations are
mitigated by some significant strengths, beginning with the use of
the very large, generally representative GERA cohort as the basis
for the study. The GERA cohort comprises an unselected sample
of adults (i.e., not selected for vision disorders or other health
conditions) drawn from members of a health care delivery system
whose members are representative of the general population in
northern California. Vision care is included for all members of
the Kaiser Permanente Health Plan and IOP measurement is a
standard component of vision examinations, making it unlikely
that the findings of the study are owing to selection bias, such as
the inclusion of IOP measurements from a less “healthy” sample
of eyes or individuals seeking care for glaucoma or other eye
conditions. We also focused on measurements taken on subjects
prior to any IOP lowering medication treatments and selected the
median value of the mean IOP of both eyes. Further, our study is
based on a very large, demographically representative and eth-
nically diverse cohort, with multiple IOP measurements available
for each participant, providing greater precision of measurement,
and consequently statistical power, than if only a single mea-
surement was taken. Further, the genotyping arrays had more
extensive genomic coverage than previously used arrays in pub-
lished studies, and the 1000 genomes imputation reference panel
was larger than those used in many previous studies, further
enhancing power to discover IOP genetic loci.
In summary, the current study demonstrates the utility of using
multiple phenotype measurements from electronic health records
in combination with a large and diverse sample for identifying
novel genetic loci underlying a complex trait such as IOP. Our
report of 40 novel loci associated with IOP substantially increased
the proportion of variance in IOP explained by specific genetic
factors. This study is an important step toward understanding the
mechanisms underlying IOP regulation and, consequently, glau-
coma risk and progression.
Methods
Study population. We report a genome-wide association study (GWAS) of IOP in
69,756 individuals from the GERA cohort. The GERA cohort comprises 110,266
adult men and women who are consented participants in the Research Program on
Genes, Environment, and Health, drawn from members of the Kaiser Permanente
Medical Care Plan, Northern California Region (KPNC); the GERA cohort has
been described in detail elsewhere54, 55. The current study population consisted of
69,756 adults, 18 years and older, who were of non-Hispanic white, Hispanic/
Latino, Asian, or African American race/ethnicity, and who had at least one
recorded IOP measurement on both eyes during the same visit between January
2006 and January 2017 (Table 1). All study procedures were approved by the
Institutional Review Board of the Kaiser Foundation Research Institute.
Phenotype definition. IOP measurements, as entered by clinicians at each vision
encounter, were captured in the electronic health records as smart variables. The
main standard equipment for measuring IOP in KPNC ophthalmology practices is
a Goldmann applanation tonometer (Haag-Streit, Bern, Switzerland), followed by a
non-contact tonometer (Nidek TonoRef II), a Tono-Pen XL, an iCare rebound
tonometer (Tiolat, Helsinki, Finland) and other equipment, including pneumo-
tonometers (Supplementary Table 11). For this analysis, we removed non-numeric
entries, extreme IOP values (≤5 and >60 mmHg), measurements taken on a single
eye, and 116,980 IOP measurements from 3,632 participants that were taken after
prescription of IOP lowering medications to exclude values influenced by treat-
ment. When there was more than one IOP measurement on a single day, if dif-
ferent methods were used, we chose the highest quality measurement based on the
method used (Goldmann applanation tonometer >iCare rebound tonometer
>non-contact tonometer >Tono-Pen XL >other/pneumotonometer)16. If the same
method was used for multiple measurements on the same day, we took the mean of
all measurements. Finally, individual’s mean IOP from both eyes for each visit was
assessed, and the individual’s median of the mean across all the visits was used for
analysis (Fig. 1). In total, 356,987 IOP measurements were included in this study.
Glaucoma cases and controls. Among the 69,756 participants included in the
current IOP study, 2,338 have been diagnosed with “glaucoma” clinically (Table 1).
We defined “glaucoma” as having at least: two diagnoses of POAG, or two diag-
noses of normal tension glaucoma, or one diagnosis of POAG and one diagnosis of
normal tension glaucoma. In all cases, at least one of the diagnoses was made by a
Kaiser Permanente ophthalmologist. For the control group, participants who had
one or more diagnosis of any type of glaucoma (e.g., pseudoexfoliation, pigmen-
tary, or PACG) were excluded. The final control sample included 58,172
participants.
Genotyping and imputation. DNA samples from GERA individuals were
extracted from Oragene kits (DNA Genotek Inc., Ottawa, ON, Canada) at KPNC
and genotyped at the Genomics Core Facility of the University of California, San
Francisco (UCSF). DNA samples were genotyped at over 665,000 SNPs on four
race/ethnicity-specific Affymetrix Axiom arrays (Affymetrix, Santa Clara, CA,
USA) optimized for individuals of European, Latino, East Asian, and African-
American ancestry56, 57. Genotype QC (quality control) procedures for the GERA
samples were performed on an array-wise basis55. SNPs with initial genotyping call
rate ≥97%, allele frequency difference (≤0.15) between males and females for
autosomal markers, and genotype concordance rate (>0.75) across duplicate
samples were included. About 94% of samples and more than 98% of genetic
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markers assayed passed QC procedures. In addition to those QC criteria, SNPs
with genotype call rates <90% were removed, as well as SNPs with a minor allele
frequency <1%.
Imputation was also conducted on an array-wise basis. Following the pre-
phasing of genotypes with Shape-IT v2.r7271958, variants were imputed from the
cosmopolitan 1000 Genomes Project reference panel (phase I integrated release;
http://1000genomes.org) using IMPUTE2 v2.3.059–61. As a QC metric, we used the
info r2 from IMPUTE2, which is an estimate of the correlation of the imputed
genotype to the true genotype62. We excluded variants with an imputation r2< 0.3,
and restricted to SNPs that had a minor allele count ≥20.
GWAS analysis and covariate adjustment. We first analyzed each of the four
race/ethnicity groups (non-Hispanic whites, Hispanic/Latinos, East Asians, and
African-Americans) separately. We performed a linear regression of each indivi-
dual’s median of the mean IOP with the following covariates: age at the median
measurement, sex, and ancestry principal components (PCs) (Supplementary
Table 12). We then performed a linear regression of the residuals on each SNP
using PLINK63 v1.9 (www.cog-genomics.org/plink/1.9/) to assess genetic associa-
tions. Data from each SNP were modeled using additive dosages to account for the
uncertainty of imputation64.
Eigenstrat65 v4.2 was used to calculate the PCs on each of the four race/
ethnicity groups54. The top 10 ancestry PCs were included as covariates for the
non-Hispanic whites, while the top six ancestry PCs were included for the three
other race/ethnicity groups. The percentage of Ashkenazi ancestry was also used as
a covariate for the non-Hispanic whites to adjust for genetic ancestry, as described
previously54.
Second, we undertook a GERA meta-analysis of IOP to combine the results of
the four race/ethnicity groups using the R66 (https://www.R-project.org) package
“meta”. We calculated fixed effects summary estimates under an additive model,
and we assessed heterogeneity index, I2 (0–100%) among groups as well as
Cochran’s Q heterogeneity statistic. At each locus, the lead SNP was defined as the
most significant SNP within a 2Mb window. New loci were defined as those that
were located more than 1Mb apart from any previously described locus.
Finally, to identify additional independent SNPs at each locus, we conducted
association analyses by including all the 47 lead SNPs identified in the GERA trans-
ethnic meta-analysis as covariates in the regression model. We assessed whether
any additional SNPs within a 2 Mb window (± 1.0 Mb with respect to the original
lead SNP) reached genome-wide significance. We report associations that replicate
at a Bonferroni-corrected significance threshold of 0.05/500 = 0.0001
(corresponding to an estimate of ~500 independent variants per locus for 2Mb
interval surrounding each of our original signals), as previously used67. An epistasis
analysis of all pairs of lead SNPs was also conducted in the four GERA race/
ethnicity groups (non-Hispanic whites, Hispanic/Latinos, East Asians and African/
Americans). For this analysis, we applied a Bonferroni-corrected significance
threshold of 0.05/4,324 = 1.2 × 10–5 (accounting for the number of SNP-pairs tested
(47*46)/2, and for the four race/ethnicity groups).
Glaucoma case–control analysis. We evaluated the associations of the 47 lead
IOP-associated SNPs with glaucoma susceptibility by logistic regression under an
additive model, and adjusting for age, sex, and ancestry PCs.
Replication of novel SNPs in an independent external cohort. To test the 40
novel GERA genome-wide significant SNPs for replication, we evaluated associa-
tions in an independent external study. GWAS summary statistics from the study
of Springelkamp et al.11, consisting of 37,930 individuals of European and Asian
descent from 19 studies, were publicly accessible. We also combined the results for
the 40 novel identified SNPs using a meta-analysis of GERA and the study of
Springelkamp et al.11. We report fixed effects results, and associations that replicate
at a strict Bonferroni threshold (P< 0.00125, to account for a total of 40 SNPs
tested).
Replication analysis of previously reported SNPs in GERA. To determine how
many of the 11 previously reported IOP loci from genetic studies replicated in the
GERA cohort, we tested 13 statistically independent lead SNPs previously reported
to be associated at a genome-wide level of significance6–9, 11, 13, 22. We used a
nominal significance level of 0.05, and a more stringent multiple testing correction
accounting for the number of SNPs tested (Bonferroni-corrected alpha level of
0.0038 ( = 0.05/13)).
GWAS heritability estimates and variance explained. SNP-based heritability
estimates were obtained for IOP using the GCTA software39, which computes the
phenotypic variance explained by all analyzed SNPs in the genome by restricted
maximum likelihood achieved using expectation maximization. We restricted the
analysis to autosomal SNPs, and a genetic relationship matrix cutoff of 0.025 was
applied. For statistical power purposes, we conducted the analysis in the largest
group of individuals from GERA, which is the non-Hispanic white.
We also estimated the variance explained by (1) the 47 lead SNPs identified in
the current study; and (2) the 13 SNPs previously identified, using a linear
regression on the IOP residuals, and including either the 47 lead SNPs or the 13
previously reported SNPs as covariates in the model. To assess the impact of
multiple IOP measurements on the proportion of variance explained, we also
estimated the variance explained by the 47 lead SNPs using a single, randomly
selected IOP measurement for each individual.
In silico analyses. To produce the most thorough list of candidate genes within the
47 identified loci, we used a Bayesian approach (CAVIARBF)68, publicly available
at https://bitbucket.org/Wenan/caviarbf. Briefly, for each of the 47 signals, we
computed each variant’s ability to explain the observed signal within a 2Mb
window (±1.0 Mb with respect to the original lead SNP) and derived, the smallest
set of variants that included the causal variant with 95% probability (95% credible
set). Previous studies69, 70 have used similar approaches to prioritize variants near
index SNPs for follow-up. These 47 credible sets included a total of 12,614 variants
in 59 annotated genes (Supplementary Data 1).
Expression of the genes that contained associated 95% credible set variants was
assessed in human ocular tissues using two publicly available databases: the
OTDB34, and EyeSAGE35, 36 publicly available at https://genome.uiowa.edu/otdb/,
and http://neibank.nei.nih.gov/EyeSAGE/index.shtml, respectively. The OTDB
contains gene expression data for 10 eye tissues from 20 normal human donors,
and the gene expression is reported as Affymetrix Probe Logarithmic Intensity
Error normalized value, as previously described34.
We then prioritized potentially causal genes for the 47 associations identified in
the GERA GWAS using DEPICT38, a previously described bioinformatics tool that
is not driven by phenotype-specific hypotheses. All the 47 lead SNPs that achieved
P< 5 × 10–8 in the GERA GWAS served as input, and information on prioritized
genes was extracted. Genes that reached a nominal significance level of 0.05 in
DEPICT were subsequently prioritized. Finally, enriched gene set/pathways and
tissues/cell types were highlighted using DEPICT38 and the same 47 lead SNPs
input.
Data availability. Genotype data of GERA participants are available from the
dbGaP (database of Genotypes and Phenotypes) under accession phs000674.v2.p2.
This includes individuals who consented to having their data shared with dbGaP.
The complete GERA data are available upon application to the KP Research Bank
(https://researchbank.kaiserpermanente.org/). The summary statistics generated in
this study are available from the corresponding authors upon reasonable request.
The GWAS summary statistics for the replication study11 are available from
(https://www.dropbox.com/sh/3j2h9qdbzjwvaj1/AABFD1eyNetiF63I5bQooYura?
dl¼0).
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